No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
- MeSH
- adipokiny krev MeSH
- ankylózující spondylitida krev patofyziologie terapie MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- stupeň závažnosti nemoci MeSH
- terapie cvičením metody MeSH
- výsledek terapie MeSH
- zdravotní stav MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adipokiny MeSH
To investigate the effect of intensive physiotherapy on disease activity and serum levels of adipocytokines in patients with ankylosing spondylitis (AS). Twenty-six patients with AS were included in this study. Intensive physiotherapy was performed twice a week for a period of 3 months. The Bath AS Disease Activity Index (BASDAI) and the Bath AS Functional Index (BASFI) were assessed at inclusion and after 3 months. Leptin, adiponectin, resistin and visfatin serum levels were analysed by ELISA assays. Patients had mild to moderate disease activity. Baseline levels of adipocytokines did not correlate with indicators of disease activity, functional status or acute-phase reactants. After the 3 months of intensive physiotherapy, BASDAI significantly decreased from 2.98 to 1.8 (p = 0.01) and BASFI improved from 2.31 to 1.37 (p = 0.05), while there were no changes in serum levels of CRP, ESR and adipocytokines. In addition, baseline levels of adipocytokines did not predict the change of disease activity or functional ability. Intensive physiotherapy effectively reduces all clinical measures of disease activity, but it is not associated with a significant change in acute-phase reactants or serum levels of adipocytokines.
Institute of Rheumatology Department of Experimental and Clinical Rheumatology Prague Czech Republic
Zobrazit více v PubMed
J Rheumatol. 1994 Dec;21(12):2286-91 PubMed
J Immunol. 2005 May 1;174(9):5789-95 PubMed
Ann Rheum Dis. 2006 Sep;65(9):1198-201 PubMed
J Immunol. 2006 Apr 1;176(7):4468-78 PubMed
Ann Rheum Dis. 2007 Apr;66(4):458-63 PubMed
Clin Rheumatol. 2008 Jun;27(6):695-700 PubMed
Arthritis Rheum. 2007 Sep;56(9):2829-39 PubMed
J Rheumatol. 2002 Apr;29(4):763-6 PubMed
Ann Rheum Dis. 2003 Oct;62(10):952-6 PubMed
Obesity (Silver Spring). 2009 Jun;17(6):1189-95 PubMed
Med Sci Sports Exerc. 2010 Mar;42(3):456-62 PubMed
Endocr Regul. 2010 Jan;44(1):25-36 PubMed
Nat Clin Pract Rheumatol. 2008 Nov;4(11):597-604 PubMed
Lancet. 2007 Apr 21;369(9570):1379-1390 PubMed
Metabolism. 2007 Oct;56(10):1383-9 PubMed
Trends Cardiovasc Med. 2007 Nov;17(8):275-83 PubMed
Rheumatology (Oxford). 2006 Mar;45(3):283-6 PubMed
J Rheumatol. 1994 Dec;21(12):2281-5 PubMed
J Rheumatol. 2005 Oct;32(10):1899-906 PubMed
Arthritis Rheum. 1984 Apr;27(4):361-8 PubMed
Curr Opin Rheumatol. 2008 Mar;20(2):203-7 PubMed
Scand J Rheumatol. 2007 Mar-Apr;36(2):101-6 PubMed
Cytokine. 2006 Sep;35(5-6):247-52 PubMed
Clin Immunol. 2009 Nov;133(2):157-70 PubMed
Ann Rheum Dis. 2003 Sep;62(9):817-24 PubMed
J Am Coll Cardiol. 2005 May 17;45(10):1563-9 PubMed
Nat Rev Immunol. 2006 Oct;6(10):772-83 PubMed
The role of resistin in inflammatory myopathies
